Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
- Conditions
- Severe Asthma
- Registration Number
- NCT03931954
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.
- Detailed Description
To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 794
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood Eosinophil count There is only one study visit. During that study visit the sample will be collected The level of eosinophils in the blood will be assessed from this blood sample and reported
Total serum IgE There is only one study visit. during that visit the sample will be collected Total serum IgE will be assessed from this blood sample and reported
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇸🇦Riyadh, Saudi Arabia